Role of RUNX2 in breast cancer development and drug resistance (Review)
- Authors:
- Wentao Si
- Chen Kan
- Leisheng Zhang
- Feifei Li
-
Affiliations: Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui 230032, P.R. China, Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province and NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China - Published online on: March 15, 2023 https://doi.org/10.3892/ol.2023.13762
- Article Number: 176
-
Copyright: © Si et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Akram M, Iqbal M, Daniyal M and Khan AU: Awareness and current knowledge of breast cancer. Biol Res. 50:332017. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O'Regan R, Torres MA and Meisel JL: Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 161:279–287. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gomathi K, Akshaya N, Srinaath N, Moorthi A and Selvamurugan N: Regulation of Runx2 by post-translational modifications in osteoblast differentiation. Life Sci. 245:1173892020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu DD, Zhang CY, Liu Y, Li J, Wang YX and Zheng SG: RUNX2 regulates osteoblast differentiation via the BMP4 signaling pathway. J Dent Res. 101:1227–1237. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Komori T: Runx2, a multifunctional transcription factor in skeletal development. J Cell Biochem. 87:1–8. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Ge C and Franceschi RT: Role of Runx2 in prostate development and stem cell function. Prostate. 81:231–241. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Westendorf JJ: Transcriptional co-repressors of Runx2. J Cell Biochem. 98:54–64. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Wei Y, Chi Y, Liu D, Yang S, Han Z and Li Z: Two-step generation of mesenchymal stem/stromal cells from human pluripotent stem cells with reinforced efficacy upon osteoarthritis rabbits by HA hydrogel. Cell Biosci. 11:62021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Wang H, Liu C, Wu Q, Su P, Wu D, Guo J, Zhou W, Xu Y, Shi L and Zhou J: MSX2 initiates and accelerates mesenchymal stem/stromal cell specification of hPSCs by regulating TWIST1 and PRAME. Stem Cell Reports. 11:497–513. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lu J and Zhang H, Pan J, Hu Z, Liu L, Liu Y, Yu X, Bai X, Cai D and Zhang H: Fargesin ameliorates osteoarthritis via macrophage reprogramming by downregulating MAPK and NF-κB pathways. Arthritis Res Ther. 23:1422021. View Article : Google Scholar : PubMed/NCBI | |
|
Kim HJ, Kim WJ and Ryoo HM: Post-translational regulations of transcriptional activity of RUNX2. Mol Cells. 43:160–167. 2020.PubMed/NCBI | |
|
Zhang Y and Duan X: A novel 90-kbp deletion of RUNX2 associated with cleidocranial dysplasia. Genes (Basel). 13:11282022. View Article : Google Scholar : PubMed/NCBI | |
|
Ukkat J, Hoang-Vu C, Trojanowicz B and Rebelo A: Osteocalcin, osteopontin and RUNX2 expression in patients' leucocytes with arteriosclerosis. Diseases. 9:192021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Ren Z, Liu B and Wei S: RUNX2 mediates renal cell carcinoma invasion through calpain2. Biol Pharm Bull. 45:1653–1659. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Wysokinski D, Blasiak J and Pawlowska E: Role of RUNX2 in breast carcinogenesis. Int J Mol Sci. 16:20969–20993. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
He F, Matsumoto Y, Asano Y, Yamamura Y, Katsuyama T, La Rose J, Tomonobu N, Komalasari NLGY, Sakaguchi M, Rottapel R and Wada J: RUNX2 phosphorylation by tyrosine kinase ABL promotes breast cancer invasion. Front Oncol. 11:6652732021. View Article : Google Scholar : PubMed/NCBI | |
|
Song X, Liu J, Liu B, Piao C, Kong C and Li Z: RUNX2 interacts with SCD1 and activates Wnt/β-catenin signaling pathway to promote the progression of clear cell renal cell carcinoma. Cancer Med. Oct 6–2022.(Epub ahead of print). | |
|
Guo Z, Zhou K, Wang Q, Huang Y, Ji J, Peng Y, Zhang X, Zheng T, Zhang Z, Chong D and Yang Z: The transcription factor RUNX2 fuels YAP1 signaling and gastric cancer tumorigenesis. Cancer Sci. 112:3533–3544. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Li N, Luo D, Hu X, Luo W, Lei G, Wang Q, Zhu T, Gu J, Lu Y and Zheng Q: RUNX2 and osteosarcoma. Anticancer Agents Med Chem. 15:881–887. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Si W, Xu X, Wan L, Lv F, Wei W, Xu X, Li W, Huang D, Zhang L and Li F: RUNX2 facilitates aggressiveness and chemoresistance of triple negative breast cancer cells via activating MMP1. Front Oncol. 12:9960802022. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrari N, McDonald L, Morris JS, Cameron ER and Blyth K: RUNX2 in mammary gland development and breast cancer. J Cell Physiol. 228:1137–1142. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Liu L, Xu X, He X, Wang G, Fan C, Zheng Q and Li F: miR-205/RunX2 axis negatively regulates CD44+/CD24− breast cancer stem cell activity. Am J Cancer Res. 10:1871–1887. 2020.PubMed/NCBI | |
|
Zhang P, Liu L, Zhang L, He X, Xu X, Lu Y and Li F: Runx2 is required for activity of CD44+/CD24−/low breast cancer stem cell in breast cancer development. Am J Transl Res. 12:2305–2318. 2020.PubMed/NCBI | |
|
Kudela E, Samec M, Koklesova L, Liskova A, Kubatka P, Kozubik E, Rokos T, Pribulova T, Gabonova E, Smolar M and Biringer K: miRNA expression profiles in luminal A breast cancer-implications in biology, prognosis, and prediction of response to hormonal treatment. Int J Mol Sci. 21:76912020. View Article : Google Scholar : PubMed/NCBI | |
|
Harbeck N and Gnant M: Breast cancer. Lancet. 389:1134–1150. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C and Piccart M: Luminal B breast cancer: Molecular characterization, clinical management, and future perspectives. J Clin Oncol. 32:2794–2803. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Loibl S and Gianni L: HER2-positive breast cancer. Lancet. 389:2415–2429. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Alexandrou S, George SM, Ormandy CJ, Lim E, Oakes SR and Caldon CE: The proliferative and apoptotic landscape of basal-like breast cancer. Int J Mol Sci. 20:6672019. View Article : Google Scholar : PubMed/NCBI | |
|
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. Arch Pathol Lab Med. 138:241–256. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Dagogo-Jack I and Shaw AT: Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 15:81–94. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S and Senkus E; ESMO Guidelines Committee. Electronic address, : simpleclinicalguidelines@esmo.org: Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 30:1194–1220. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tosello G, Torloni MR, Mota BS, Neeman T and Riera R: Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev. 3:CD0112762018.PubMed/NCBI | |
|
Maughan KL, Lutterbie MA and Ham PS: Treatment of breast cancer. Am Fam Physician. 81:1339–1346. 2010.PubMed/NCBI | |
|
Pondé NF, Zardavas D and Piccart M: Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol. 16:27–44. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Waks AG and Winer EP: Breast cancer treatment: A review. JAMA. 321:288–300. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Abderrahman B and Jordan VC: Telling details of breast-cancer recurrence. Nature. 553:1552018. View Article : Google Scholar | |
|
Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y and Ohki M: t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA. 88:10431–10434. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Schlegelberger B and Heller PG: RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM). Semin Hematol. 54:75–80. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ito Y, Bae SC and Chuang LS: The RUNX family: developmental regulators in cancer. Nat Rev Cancer. 15:81–95. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cecconi D, Brandi J, Manfredi M, Serena M, Dalle Carbonare L, Deiana M, Cheri S, Parolini F, Gandini A, Marchetto G, et al: Runx2 stimulates neoangiogenesis through the Runt domain in melanoma. Sci Rep. 9:80522019. View Article : Google Scholar : PubMed/NCBI | |
|
Vitale E, Sauta E, Gugnoni M, Torricelli F, Manicardi V and Ciarrocchi A: A multimodal integrative approach to model transcriptional addiction of thyroid cancer on RUNX2. Cancer Commun (Lond). 42:892–896. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Guan Y, Zhang Y, Hao L and Nie Z: CircRNA_102272 promotes cisplatin-resistance in hepatocellular carcinoma by decreasing MiR-326 targeting of RUNX2. Cancer Manag Res. 12:12527–12534. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Matthijssens F, Sharma ND, Nysus M, Nickl CK, Kang H, Perez DR, Lintermans B, Van Loocke W, Roels J, Peirs S, et al: RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. J Clin Invest. 131:e1415662021. View Article : Google Scholar : PubMed/NCBI | |
|
Ji Q, Cai G, Liu X, Zhang Y, Wang Y, Zhou L, Sui H and Li Q: MALAT1 regulates the transcriptional and translational levels of proto-oncogene RUNX2 in colorectal cancer metastasis. Cell Death Dis. 10:3782019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang F, Su T and Xiao M: RUNX3-regulated circRNA METTL3 inhibits colorectal cancer proliferation and metastasis via miR-107/PER3 axis. Cell Death Dis. 13:5502022. View Article : Google Scholar : PubMed/NCBI | |
|
Liu H, Xue Q, Cai H, Jiang X, Cao G, Chen T, Chen Y and Wang D: RUNX3-mediated circDYRK1A inhibits glutamine metabolism in gastric cancer by up-regulating microRNA-889-3p-dependent FBXO4. J Transl Med. 20:1202022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Tang W, Yang S, He P, Wang J, Gaedcke J, Ströbel P, Azizian A, Ried T, Gaida MM, et al: NO•/RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer. Int J Cancer. 146:3160–3169. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Mevel R, Draper JE, Lie-A-Ling M, Kouskoff V and Lacaud G: RUNX transcription factors: Orchestrators of development. Development. 146:dev1482962019. View Article : Google Scholar : PubMed/NCBI | |
|
Komori T: Regulation of proliferation, differentiation and functions of osteoblasts by Runx2. Int J Mol Sci. 20:16942019. View Article : Google Scholar : PubMed/NCBI | |
|
Nagata K, Hojo H, Chang SH, Okada H, Yano F, Chijimatsu R, Omata Y, Mori D, Makii Y, Kawata M, et al: Runx2 and Runx3 differentially regulate articular chondrocytes during surgically induced osteoarthritis development. Nat Commun. 13:61872022. View Article : Google Scholar : PubMed/NCBI | |
|
Villanueva F, Araya H, Briceño P, Varela N, Stevenson A, Jerez S, Tempio F, Chnaiderman J, Perez C, Villarroel M, et al: The cancer-related transcription factor RUNX2 modulates expression and secretion of the matricellular protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis. J Cell Physiol. 234:13659–13679. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Senbanjo LT, AlJohani H, Majumdar S and Chellaiah MA: Characterization of CD44 intracellular domain interaction with RUNX2 in PC3 human prostate cancer cells. Cell Commun Signal. 17:802019. View Article : Google Scholar : PubMed/NCBI | |
|
Yin X, Teng X, Ma T, Yang T, Zhang J, Huo M, Liu W, Yang Y, Yuan B, Yu H, et al: RUNX2 recruits the NuRD(MTA1)/CRL4B complex to promote breast cancer progression and bone metastasis. Cell Death Differ. 29:2203–2217. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Chan WCW, Tan Z, To MKT and Chan D: Regulation and role of transcription factors in osteogenesis. Int J Mol Sci. 22:54452021. View Article : Google Scholar : PubMed/NCBI | |
|
Coffman JA: Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biol Int. 27:315–324. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Han X, Feng J, Guo T, Loh YE, Yuan Y, Ho TV, Cho CK, Li J, Jing J, Janeckova E, et al: Runx2-Twist1 interaction coordinates cranial neural crest guidance of soft palate myogenesis. Elife. 10:e623872021. View Article : Google Scholar : PubMed/NCBI | |
|
Shu HS, Liu YL, Tang XT, Zhang XS, Zhou B, Zou W and Zhou BO: Tracing the skeletal progenitor transition during postnatal bone formation. Cell Stem Cell. 28:2122–2136.e3. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu TM and Lee EH: Transcriptional regulatory cascades in Runx2-dependent bone development. Tissue Eng Part B Rev. 19:254–263. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Qin X, Jiang Q, Nagano K, Moriishi T, Miyazaki T, Komori H, Ito K, Mark KV, Sakane C, Kaneko H and Komori T: Runx2 is essential for the transdifferentiation of chondrocytes into osteoblasts. PLoS Genet. 16:e10091692020. View Article : Google Scholar : PubMed/NCBI | |
|
Owens TW, Rogers RL, Best S, Ledger A, Mooney AM, Ferguson A, Shore P, Swarbrick A, Ormandy CJ, Simpson PT, et al: Runx2 is a novel regulator of mammary epithelial cell fate in development and breast cancer. Cancer Res. 74:5277–5286. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Inman CK and Shore P: The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem. 278:48684–48689. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Sato M, Morii E, Komori T, Kawahata H, Sugimoto M, Terai K, Shimizu H, Yasui T, Ogihara H, Yasui N, et al: Transcriptional regulation of osteopontin gene in vivo by PEBP2alphaA/CBFA1 and ETS1 in the skeletal tissues. Oncogene. 17:1517–1525. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL and Stein GS: Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev. 25:589–600. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kim B, Kim H, Jung S, Moon A, Noh DY, Lee ZH, Kim HJ and Kim HH: A CTGF-RUNX2-RANKL axis in breast and prostate cancer cells promotes tumor progression in bone. J Bone Miner Res. 35:155–166. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ma F, Xie Y, Lei Y, Kuang Z and Liu X: The microRNA-130a-5p/RUNX2/STK32A network modulates tumor invasive and metastatic potential in non-small cell lung cancer. BMC Cancer. 20:5802020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu CY, Li L, Chen SL, Yang X, Zhang CZ and Cao Y: A Zic2/Runx2/NOLC1 signaling axis mediates tumor growth and metastasis in clear cell renal cell carcinoma. Cell Death Dis. 12:3192021. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen-Solal KA, Boregowda RK and Lasfar A: RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression. Mol Cancer. 14:1372015. View Article : Google Scholar : PubMed/NCBI | |
|
Tandon M, Gokul K, Ali SA, Chen Z, Lian J, Stein GS and Pratap J: Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells. Mol Cancer. 11:272012. View Article : Google Scholar : PubMed/NCBI | |
|
Pranavkrishna S, Sanjeev G, Akshaya RL, Rohini M and Selvamurugan N: A computational approach on studying the regulation of TGF-β1-stimulated Runx2 expression by MicroRNAs in human breast cancer cells. Comput Biol Med. 137:1048232021. View Article : Google Scholar : PubMed/NCBI | |
|
Vishal M, Swetha R, Thejaswini G, Arumugam B and Selvamurugan N: Role of Runx2 in breast cancer-mediated bone metastasis. Int J Biol Macromol. 99:608–614. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fang Y, Xue Z, Zhao L, Yang X, Yang Y, Zhou X, Feng S and Chen K: Calycosin stimulates the osteogenic differentiation of rat calvarial osteoblasts by activating the IGF1R/PI3K/Akt signaling pathway. Cell Biol Int. 43:323–332. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tandon M, Othman AH, Ashok V, Stein GS and Pratap J: The role of Runx2 in facilitating autophagy in metastatic breast cancer cells. J Cell Physiol. 233:559–571. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Schneider JG, Amend SR and Weilbaecher KN: Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions. Bone. 48:54–65. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Li XQ, Lu JT, Tan CC, Wang QS and Feng YM: RUNX2 promotes breast cancer bone metastasis by increasing integrin α5-mediated colonization. Cancer Lett. 380:78–86. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Si W, Zhou J, Zhao Y, Zheng J and Cui L: SET7/9 promotes multiple malignant processes in breast cancer development via RUNX2 activation and is negatively regulated by TRIM21. Cell Death Dis. 11:1512020. View Article : Google Scholar : PubMed/NCBI | |
|
Morikawa M, Derynck R and Miyazono K: TGF-β and the TGF-β family: Context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol. 8:a0218732016. View Article : Google Scholar : PubMed/NCBI | |
|
Larson C, Oronsky B, Carter CA, Oronsky A, Knox SJ, Sher D and Reid TR: TGF-beta: A master immune regulator. Expert Opin Ther Targets. 24:427–438. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Li XQ, Du X, Li DM, Kong PZ, Sun Y, Liu PF, Wang QS and Feng YM: ITGBL1 is a Runx2 transcriptional target and promotes breast cancer bone metastasis by activating the TGFβ signaling pathway. Cancer Res. 75:3302–3313. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Taipaleenmäki H, Browne G, Akech J, Zustin J, van Wijnen AJ, Stein JL, Hesse E, Stein GS and Lian JB: Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res. 75:1433–1444. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Croset M, Pantano F, Kan CWS, Bonnelye E, Descotes F, Alix-Panabières C, Lecellier CH, Bachelier R, Allioli N, Hong SS, et al: miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes. Cancer Res. 78:5259–5273. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao P, Guan H, Dai Z, Ma Y, Zhao Y and Liu D: Long noncoding RNA DLX6-AS1 promotes breast cancer progression via miR-505-3p/RUNX2 axis. Eur J Pharmacol. 865:1727782019. View Article : Google Scholar : PubMed/NCBI | |
|
Rohini M, Gokulnath M, Miranda PJ and Selvamurugan N: miR-590-3p inhibits proliferation and promotes apoptosis by targeting activating transcription factor 3 in human breast cancer cells. Biochimie. 154:10–18. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Batlle E and Clevers H: Cancer stem cells revisited. Nat Med. 23:1124–1134. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Babaei G, Aziz SGG and Jaghi NZZ: EMT, cancer stem cells and autophagy; the three main axes of metastasis. Biomed Pharmacother. 133:1109092021. View Article : Google Scholar : PubMed/NCBI | |
|
Peitzsch C, Tyutyunnykova A, Pantel K and Dubrovska A: Cancer stem cells: The root of tumor recurrence and metastases. Semin Cancer Biol. 44:10–24. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ishiguro T, Ohata H, Sato A, Yamawaki K, Enomoto T and Okamoto K: Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications. Cancer Sci. 108:283–289. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T, Wallwiener M, et al: Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 31:539–544. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Butti R, Gunasekaran VP, Kumar TVS, Banerjee P and Kundu GC: Breast cancer stem cells: Biology and therapeutic implications. Int J Biochem Cell Biol. 107:38–52. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Dittmer J: Breast cancer stem cells: Features, key drivers and treatment options. Semin Cancer Biol. 53:59–74. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Katoh M: Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (review). Int J Oncol. 51:1357–1369. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ibrahim SA, Gadalla R, El-Ghonaimy EA, Samir O, Mohamed HT, Hassan H, Greve B, El-Shinawi M, Mohamed MM and Götte M: Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways. Mol Cancer. 16:572017. View Article : Google Scholar : PubMed/NCBI | |
|
Colacino JA, Azizi E, Brooks MD, Harouaka R, Fouladdel S, McDermott SP, Lee M, Hill D, Madden J, Boerner J, et al: Heterogeneity of human breast stem and progenitor cells as revealed by transcriptional profiling. Stem Cell Reports. 10:1596–1609. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, Martin-Trevino R, Shang L, McDermott SP, Landis MD, et al: Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports. 2:78–91. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zöller M: CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 11:254–267. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Vikram R, Chou WC, Hung SC and Shen CY: Tumorigenic and metastatic role of CD44−/low/CD24−/low cells in luminal breast cancer. Cancers (Basel). 12:12392020. View Article : Google Scholar : PubMed/NCBI | |
|
Yan X, Han D, Chen Z, Han C, Dong W, Han L, Zou L, Zhang J, Liu Y and Chai J: RUNX2 interacts with BRG1 to target CD44 for promoting invasion and migration of colorectal cancer cells. Cancer Cell Int. 20:5052020. View Article : Google Scholar : PubMed/NCBI | |
|
Knutson TP, Truong TH, Ma S, Brady NJ, Sullivan ME, Raj G, Schwertfeger KL and Lange CA: Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs. J Hematol Oncol. 10:892017. View Article : Google Scholar : PubMed/NCBI | |
|
Valenti MT, Serafini P, Innamorati G, Gili A, Cheri S, Bassi C and Dalle Carbonare L: Runx2 expression: A mesenchymal stem marker for cancer. Oncol Lett. 12:4167–4172. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fritz AJ, Hong D, Boyd J, Kost J, Finstaad KH, Fitzgerald MP, Hanna S, Abuarqoub AH, Malik M, Bushweller J, et al: RUNX1 and RUNX2 transcription factors function in opposing roles to regulate breast cancer stem cells. J Cell Physiol. 235:7261–7272. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Muley H, Fadó R, Rodriguez-Rodriguez R and Casals N: Drug uptake-based chemoresistance in breast cancer treatment. Biochem Pharmacol. 177:1139592020. View Article : Google Scholar : PubMed/NCBI | |
|
Dingwall S, Lee JB, Guezguez B, Fiebig A, McNicol J, Boreham D, Collins TJ and Bhatia M: Neoplastic human embryonic stem cells as a model of radiation resistance of human cancer stem cells. Oncotarget. 6:22258–22269. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Najafi M, Mortezaee K and Majidpoor J: Cancer stem cell (CSC) resistance drivers. Life Sci. 234:1167812019. View Article : Google Scholar : PubMed/NCBI | |
|
Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, Sastry N, Hu B and Cheng SY: Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 10:8721–8743. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Garcia-Mayea Y, Mir C, Masson F, Paciucci R and LLeonart ME: Insights into new mechanisms and models of cancer stem cell multidrug resistance. Semin Cancer Biol. 60:166–180. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Smith AG and Macleod KF: Autophagy, cancer stem cells and drug resistance. J Pathol. 247:708–718. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG and Di Fiore PP: Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell. 140:62–73. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Phillips TM, McBride WH and Pajonk F: The response of CD24(−/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 98:1777–1785. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ryoo IG, Choi BH and Kwak MK: Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells. Oncotarget. 6:8167–8184. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bai J, Chen WB, Zhang XY, Kang XN, Jin LJ, Zhang H and Wang ZY: HIF-2α regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer via PI3K/AKT/mTOR signaling. World J Stem Cells. 12:87–99. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bai X, Ni J, Beretov J, Graham P and Li Y: Cancer stem cell in breast cancer therapeutic resistance. Cancer Treat Rev. 69:152–163. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Leccia F, Del Vecchio L, Mariotti E, Di Noto R, Morel AP, Puisieux A, Salvatore F and Ansieau S: ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells. Mol Cancer. 13:2132014. View Article : Google Scholar : PubMed/NCBI | |
|
Sadikovic B, Thorner P, Chilton-Macneill S, Martin JW, Cervigne NK, Squire J and Zielenska M: Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer. 10:2022010. View Article : Google Scholar : PubMed/NCBI | |
|
Roos A, Satterfield L, Zhao S, Fuja D, Shuck R, Hicks MJ, Donehower LA and Yustein JT: Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis. Br J Cancer. 113:1289–1297. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sugimoto H, Nakamura M, Yoda H, Hiraoka K, Shinohara K, Sang M, Fujiwara K, Shimozato O, Nagase H and Ozaki T: Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Cell Death Discov. 1:150102015. View Article : Google Scholar : PubMed/NCBI | |
|
Ozaki T, Nakamura M, Ogata T, Sang M, Yoda H, Hiraoka K, Sang M and Shimozato O: Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63. Oncotarget. 7:71937–71950. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jeselsohn R, Cornwell M, Pun M, Buchwalter G, Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C, Fu X, et al: Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. Proc Natl Acad Sci USA. 114:E4482–E4491. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Geter PA, Ernlund AW, Bakogianni S, Alard A, Arju R, Giashuddin S, Gadi A, Bromberg J and Schneider RJ: Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming. Genes Dev. 31:2235–2249. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Othman A, Winogradzki M, Patel S, Holmes W, Blank A and Pratap J: The role of Runx2 in microtubule acetylation in bone metastatic breast cancer cells. Cancers (Basel). 14:34362022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang XX, Ye FG, Zhang J, Li JJ, Chen QX, Lin PY and Song CG: Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by suppressing RUNX2. Cancer Manag Res. 10:4393–4400. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Huang L, Zhang L and Chen X: Updated review of advances in microRNAs and complex diseases: Taxonomy, trends and challenges of computational models. Brief Bioinform. 23:bbac3582022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Xie D, Zhao Q and You ZH: MicroRNAs and complex diseases: From experimental results to computational models. Brief Bioinform. 20:515–539. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Yan CC, Zhang X and You ZH: Long non-coding RNAs and complex diseases: From experimental results to computational models. Brief Bioinform. 18:558–576. 2017.PubMed/NCBI | |
|
Wang CC, Han CD, Zhao Q and Chen X: Circular RNAs and complex diseases: From experimental results to computational models. Brief Bioinform. 22:bbab2862021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao W, Geng D, Li S, Chen Z and Sun M: LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer. Cancer Med. 7:842–855. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Xu J, Wu KJ, Jia QJ and Ding XF: Roles of miRNA and lncRNA in triple-negative breast cancer. J Zhejiang Univ Sci B. 21:673–689. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kong X, Duan Y, Sang Y, Li Y, Zhang H, Liang Y, Liu Y, Zhang N and Yang Q: LncRNA-CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215. J Cell Physiol. 234:9105–9117. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sang Y, Chen B, Song X, Li Y, Liang Y, Han D, Zhang N, Zhang H, Liu Y, Chen T, et al: circRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p/FOXO3a axis in breast cancer. Mol Ther. 27:1638–1652. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yin X, Wang P, Yang T, Li G, Teng X, Huang W and Yu H: Identification of key modules and genes associated with breast cancer prognosis using WGCNA and ceRNA network analysis. Aging (Albany NY). 13:2519–2538. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Joshi H and Press MF: Molecular oncology of breast cancer. The Breast. Elsevier; Amsterdam, The Netherlands: pp. pp282–307.e5. 2018, Available online:. https://www.sciencedirect.com/science/article/pii/B978032335955900022230–May. 2021 View Article : Google Scholar | |
|
Dzobo K and Sinkala M: Cancer stem cell marker CD44 plays multiple key roles in human cancers: immune suppression/evasion, drug resistance, epithelial-mesenchymal transition, and metastasis. OMICS. 25:313–332. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Fillmore C and Kuperwasser C: Human breast cancer stem cell markers CD44 and CD24: Enriching for cells with functional properties in mice or in man? Breast Cancer Res. 9:3032007. View Article : Google Scholar : PubMed/NCBI | |
|
Tomita H, Tanaka K, Tanaka T and Hara A: Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget. 7:11018–11032. 2016. View Article : Google Scholar : PubMed/NCBI |
